Technology
Health
Biotechnology

Xenon Pharmaceuticals

$10.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.33 (3.38%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell XENE and other stocks, options, ETFs, and crypto commission-free!

About

Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Read More Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Employees
92
Headquarters
Burnaby, British Columbia
Founded
1996
Market Cap
259.78M
Price-Earnings Ratio
Dividend Yield
Average Volume
176.63K
High Today
$10.10
Low Today
$9.70
Open Price
$9.87
Volume
27.75K
52 Week High
$15.92
52 Week Low
$5.41

Collections

Technology
Health
Biotechnology
Therapy
2014 IPO
Canada
North America

News

NasdaqMay 7

Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia, May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2019 and provided a corporate update. Dr. Simon Pimstone, Xenon's Chief Executive Officer, said, "We contin...

16
Yahoo FinanceApr 30

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update

BURNABY, British Columbia, April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, May 7, 2019. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please di...

14

Earnings

-$0.63
-$0.45
-$0.26
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.